Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma
Matthew S. Davids(Dana-Farber Cancer Institute), Constantine S. Tam(The Alfred Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Gottfried von Keudell(Beth Israel Deaconess Medical Center), Francine M. Foss(Yale Cancer Center), Rod Humerickhouse(Abbott Fund), John F. Seymour(The Royal Melbourne Hospital), Jonathon B. Cohen(Emory University), David C. Fisher(Dana-Farber Cancer Institute), Craig A. Portell(University of Virginia)
Cited by 28
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k